Synpromics Raises £5.2M of New Investment

Synpromics Raises £5.2M of New Investment
19.04.2017 08:30 am

Synpromics Raises £5.2M of New Investment

Investment Management

Synpromics Ltd, the leading synthetic promoter and gene control company, is delighted to announce that it has completed a financing round of £5.2M. Participants included existing investors Calculus Capital, the Scottish Investment Bank, the investment arm of Scottish Enterprise and private shareholders.

Synpromics has grown rapidly over the past two years as it expanded its portfolio of international customers. These include leading gene therapy companies and multinational technology corporations, most recently GE Healthcare.

The majority of the new investment will be used to further develop and exemplify Synpromics proprietary PromPT™ synthetic promoter design platform. PromPT™ enables the design of unique synthetic promoters which give precise control of gene function in many areas of gene medicine including gene therapy, cell therapy and gene editing. The Company is also preparing to move into a larger, new purpose built, facility.

David Venables, CEO of Synpromics, commented “Since our last fundraising round 18 months ago the business has grown rapidly as we’ve signed more commercial partnerships with companies in the US and Europe. We see an exciting opportunity to fund further rapid expansion of our business, supported by our innovative science and novel capabilities.”

Alexandra Lindsay, Investment Director at Calculus Capital, added “We have been delighted with the progress which Synpromics has made since we made our first investment some 18 months ago. They have a very strong team and the technology has been clearly validated through partnerships with some of the world’s leading gene medicine companies.”

Kerry Sharp, Head of the Scottish Investment Bank, said “Having supported Synpromics from an early stage it is great to see the progress that has been achieved to develop and grow the business in the highly dynamic synthetic biology industry. We look forward to continuing to work with the company, both from an investment perspective and through our account management support, to deliver its long term growth ambition.”

Related News

Profile: UK-based Forte Securities selected Axia for their investment and custody operations

Profile Software, a leading financial solutions provider, announced today a new partnership in the United Kingdom with... Read more »

Corfinancial: ‘remote working during market turmoil has not affected our clients using Salerio’

corfinancial, a leading provider of specialist software and services to the financial services sector, reports that its clients have enjoyed uninterrupted... Read more »

TrackInsight names Nasdaq as its exclusive distributor in North America

TrackInsight (www.trackinsight.com), the leading global independent ETF analytics platform, has named Nasdaq its... Read more »

Equiniti rebrands as EQ

Equiniti, the international technology-led services and payments specialist, is delighted to announce that it is becoming EQ.

EQ provides accessible digital services for... Read more »

Hoxton Ventures announces close of its second fund, backed by British Patient Capital

Hoxton Ventures announced the final close today of Hoxton Ventures II L.P., an early stage European venture capital fund building on the firm’s record of finding and... Read more »

Trustly announces strategic minority investment by a consortium of investors to support further expansion

BlackRock Private Equity Partners, through its private equity funds and accounts under management, together with a consortium of institutional investors, including among others... Read more »

Magazine
ALL
Free Newsletter Sign-up
+44 (0) 208 819 32 53 +44 (0) 173 261 71 47
Download Our Mobile App
Financial It Youtube channel